SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

Veronique Vitart, Igor Rudan, Caroline Hayward, Nicola K. Gray, James Floyd, Colin N.A. Palmer, Sara A. Knott, Ivana Kolcic, Xinhua Shu

Research output: Contribution to journalArticle

Abstract

Uric acid is the end product of purine metabolism in humans and great apes, which have lost hepatic uricase activity, leading to uniquely high serum uric acid concentrations (200–500 muM) compared with other mammals (3–120 muM)1. About 70% of daily urate disposal occurs via the kidneys, and in 5–25% of the human population, impaired renal excretion leads to hyperuricemia2. About 10% of people with hyperuricemia develop gout, an inflammatory arthritis that results from deposition of monosodium urate crystals in the joint. We have identified genetic variants within a transporter gene, SLC2A9, that explain 1.7–5.3% of the variance in serum uric acid concentrations, following a genome-wide association scan in a Croatian population sample.

Original languageEnglish
Pages (from-to)437-442
Number of pages6
JournalNature Genetics
Volume40
DOIs
Publication statusPublished - 1 Mar 2008

Keywords

  • gout
  • uric acid
  • purine metabolism

Fingerprint Dive into the research topics of 'SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout'. Together they form a unique fingerprint.

  • Cite this

    Vitart, V., Rudan, I., Hayward, C., Gray, N. K., Floyd, J., Palmer, C. N. A., Knott, S. A., Kolcic, I., & Shu, X. (2008). SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 40, 437-442. https://doi.org/10.1038/ng.106